Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Nasdaq Resumes Trading in Inno Holdings Inc.

Nasdaq Resumes Trading in Inno Holdings Inc.

The Nasdaq Stock Market has resumed trading of Inno Holdings Inc. (INHD) at noon on July 31, 2026, following a trading halt that began on June 8, 2026. The reason for the halt was not disclosed in the announcement. Investors can now trade the company’s shares again on Nasdaq.

Cycurion Announces a Warrant Inducement Transaction for $4.5 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Cycurion Announces a Warrant Inducement Transaction for $4.5 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Cycurion, a Nasdaq-listed cybersecurity and AI solutions provider, has entered into a warrant inducement transaction with an institutional investor, raising approximately $4.5 million in gross proceeds through the immediate exercise of warrants. In return, the investor receives new warrants to purchase additional shares at a higher exercise price, …

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, announced a technological milestone for their quantum sampling workflow platform, demonstrating a complete end-to-end hybrid quantum-classical analytical process for clinical trial data analytics. This advancement supports processing high-dimensional biomedical datasets with enha…

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results

IRADIMED CORPORATION reported Q2 2026 revenue of $20.5 million, a slight increase from Q2 2025, and earnings per share of $0.41 GAAP and $0.46 non-GAAP. The company launched its new 3870 MR IV pump with positive initial market acceptance and expects revenue and earnings growth in the back half of 2026, reaffirming full-year guidance. A quarterly ca…

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Moleculin Biotech announced positive interim blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia (AML). The trial showed a 37% composite complete remission rate (CRc) even in patients who failed prior venetoclax treatment, significantly outperformi…

Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended June 30, 2026 and Declaration of Distributions on Common Stock for the Months Ending October 31, November 30, and December 31, 2026

Oxford Square Capital Corp. Announces Net Asset Value and Selected Financial Results for the Quarter Ended June 30, 2026 and Declaration of Distributions on Common Stock for the Months Ending October 31, November 30, and December 31, 2026

Oxford Square Capital Corp. announced its net asset value, financial results for Q2 2026, and declared common stock distributions for October through December 2026. The company reported a slight decline in NAV to $1.29 per share from $1.32, net investment income of approximately $5.1 million, and total investment income of $9.4 million for the quar…

Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026

Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026

Picard Medical, Inc., through its subsidiary SynCardia Systems, presented for the first time the integrated architecture of its Emperor Total Artificial Heart (Emperor TAH) at the IEEE EMBC 2026 conference. This next-generation system combines the proven SynCardia Total Artificial Heart ventricles with a new patent-pending Emperor Drive System (EDS…

Mobilicom to Report Financial and Operational Results for the Six Months Ended June 30, 2026, on Thursday, August 13, 2026

Mobilicom to Report Financial and Operational Results for the Six Months Ended June 30, 2026, on Thursday, August 13, 2026

Mobilicom Limited, a provider of cybersecurity and robust solutions for drones and robotics, announced that it will release its financial and operational results for the six months ended June 30, 2026, on August 13, 2026, after Nasdaq market close. A conference call and webcast will follow for management to discuss results and recent developments. …

Space-Eyes and McKinley Acquisition Corp. Announce Definitive Business Combination Agreement to Deliver AI-Driven Counter Drone Technology and Geospatial Intelligence Worldwide

Space-Eyes and McKinley Acquisition Corp. Announce Definitive Business Combination Agreement to Deliver AI-Driven Counter Drone Technology and Geospatial Intelligence Worldwide

Space-Eyes, a U.S.-based geospatial intelligence and AI-powered counter-unmanned aerial system provider, has agreed to merge with McKinley Acquisition Corp. in a business combination expected to close in Q4 2026. The combined company will trade on Nasdaq under the ticker CUAS with a pro forma equity valuation of $638 million. The transaction includ…

Wearable Devices Announces Pricing of $3.3 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

Wearable Devices Announces Pricing of $3.3 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

Wearable Devices Ltd. has entered into a private placement agreement with a single institutional investor to raise approximately $3.3 million through the issuance of 1,000,000 shares and accompanying warrants exercisable over five years. The capital raised will fund commercialization of Mudra products, development of next-generation devices, AI6 La…

Acorn – Provider of Monitoring and Control Solutions for Mission-Critical Assets Hosts Q2 Earnings Call Thursday Aug. 6th at 11am ET

Acorn – Provider of Monitoring and Control Solutions for Mission-Critical Assets Hosts Q2 Earnings Call Thursday Aug. 6th at 11am ET

Acorn Energy, Inc., through its subsidiary OmniMetrix, will report its Q2 2026 earnings and hold a conference call on August 6th. The company specializes in wireless remote monitoring and control solutions for critical infrastructure such as generators, gas pipelines, cell towers, and data centers, serving commercial, governmental, and residential …

Dragonfly Energy Announces Strategic Acquisition of Dakota Lithium Assets, Expanding Into New Markets

Dragonfly Energy Announces Strategic Acquisition of Dakota Lithium Assets, Expanding Into New Markets

Dragonfly Energy Holdings Corp. announced the acquisition of substantially all operating assets of Dakota Lithium, expanding its presence in marine, outdoor recreation, powersports, and other specialty battery markets. With Dakota Lithium generating approximately $12 million in net revenue in 2025 despite product availability constraints, Dragonfly…

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Medicus Pharma announced that the UAE Department of Health has granted Investigational New Drug authorization for the PRECISION-E2 Phase 2a study evaluating Teverelix® in women with moderate-to-severe endometriosis. This study is a pioneering genomics-guided precision medicine trial aiming to optimize treatment by integrating genetic, pharmacologic…

YXT.com Regains Compliance with Nasdaq Minimum Bid Price Requirement

YXT.com Regains Compliance with Nasdaq Minimum Bid Price Requirement

YXT.com Group Holding Limited has successfully regained compliance with Nasdaq's minimum bid price requirement by increasing its ADS ratio from 1:3 to 1:30, resulting in the ADS closing price meeting or exceeding $1.00 for 10 consecutive business days. This reinstates the company’s standing on the Nasdaq exchange after earlier notices of non-compli…